William Blair & Company
ELEV

William Blair & Company’s Elevation Oncology ELEV Stock Holding History

William Blair & Company’s Portfolio ELEV Stock Details ELEV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60,000
Closed -$15.5K – 1847
2025
Q1 		$15.5K Buy
+60,000
New +$34.3K ﹤0.01% 1679

Other funds holding ELEV

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

William Blair & Company's ELEV Position: Q2 2025 in Review

William Blair & Company sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 60,000 shares — an estimated $15.5K sold.

William Blair & Company first reported a position in ELEV in Q1 2025 and held it in 1 quarter. The position peaked at $15.5K in Q1 2025. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • William Blair & Company reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • William Blair & Company sold 60,000 Elevation Oncology shares in Q2 2025, an estimated $15.5K.
  • William Blair & Company first reported a position in Elevation Oncology in Q1 2025 and held it in 1 quarter.
  • William Blair & Company's Elevation Oncology position peaked at $15.5K in Q1 2025.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on William Blair & Company's 13F filing for Q2 2025, filed 24 Jul 2025.